<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055167</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-NSCLC-006</org_study_id>
    <nct_id>NCT05055167</nct_id>
  </id_info>
  <brief_title>Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC</brief_title>
  <official_title>A Phase II Study of Envafolimab as First-line Treatment of Aged Patients With High PD-L1 Expression Stage in Advanced Non-small-cell Lung Cancer(NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Xiamen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Explore the efficacy and safety of Envafolimab in first line treatment of elderly patients&#xD;
      with locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression,&#xD;
      view to providing better treatment options for elderly patients with high PD-L1 expression&#xD;
      and improving the survival and prognosis of patients .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>48 months</time_frame>
    <description>The proportion of subjects who achieve Complete Response (CR) and Partial Response (PR) by the best response from the first dose of Almonertinib to the end of study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-small Cell Lung Cancer Stage IV</condition>
  <arm_group>
    <arm_group_label>Envafolimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elderly NSCLC Patients with high PD-L1 expression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Envafolimab</intervention_name>
    <description>single agent, 300mg Q3W IH until disease progressed</description>
    <arm_group_label>Envafolimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
          -  Age strictly at least 70 years.&#xD;
&#xD;
          -  Cytologically or histologically proven NSCLC(adenocarcinoma, epidermoid carcinoma,&#xD;
             large-cell carcinoma) of locally advanced (stage IIIb/IIIc), metastatic, or relapsing&#xD;
             (stage IV) according to the American Joint Committee on Cancer Staging Handbook.&#xD;
&#xD;
          -  Presence of at least one measurable target lesion (RECIST rules) in a non irradiated&#xD;
             region.&#xD;
&#xD;
          -  No previous systemic chemotherapy for lung cancer.&#xD;
&#xD;
          -  PD-L1≥50% in tissue samples detected by immunohistochemistry.&#xD;
&#xD;
          -  PS 0 or 1.&#xD;
&#xD;
          -  Life expectancy sup 12 weeks.&#xD;
&#xD;
          -  Normal hematologic function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  EGFR-sensitive mutations or ALK rearrangements&#xD;
&#xD;
          -  Previous treatment with immune checkpoint inhibitors&#xD;
&#xD;
          -  Presence of symptomatic brain metastases；&#xD;
&#xD;
          -  Chinese patent medicine with anti-lung cancer indications or immunoregulatory drugs&#xD;
             (including thymopeptide, interferon and interleukin, except for the local use of&#xD;
             pleural effusion control) for systemic treatment；&#xD;
&#xD;
          -  Another previous or concomitant cancer, except for basocellular cancer of the skin or&#xD;
             treated cervical cancer in situ；&#xD;
&#xD;
          -  Concurrent administration of one or several other antitumor therapies；&#xD;
&#xD;
          -  Concurrent participation in another clinical trial；&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic treatment occurred within 2 years prior&#xD;
             to initial；&#xD;
&#xD;
          -  Systemic glucocorticoid therapy or any other form of immunosuppressive therapy within&#xD;
             7 days prior to initial administration；&#xD;
&#xD;
          -  Contraindication to the study drugs；&#xD;
&#xD;
          -  Has not fully recovered from toxicity and/or complications caused by any intervention&#xD;
             prior to the commencement of treatment (i.e., grade 1 or baseline, excluding fatigue&#xD;
             or hair loss);&#xD;
&#xD;
          -  A history of human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          -  Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number&#xD;
             detected greater than the upper limit of normal value in the laboratory of the&#xD;
             research center);&#xD;
&#xD;
          -  Active HCV infected;&#xD;
&#xD;
          -  Recent vaccination within 30 days before the first administration (cycle 1, day 1);&#xD;
&#xD;
          -  Other severe concurrent disorders that occurred during the prior six months before&#xD;
             enrollment (myocardial infection, severe or unstable angor, NYHA class 3 or 4&#xD;
             congestive heart failure, transient or constituted cerebral ischemic attack,&#xD;
             psychiatric or neurological disorders preventing the patient from understanding the&#xD;
             trial, uncontrolled infections).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

